EP Patent

EP1467970B1 — Hydroxynaphthyridinone carboxamides useful as hiv integrase inhibitors

Assigned to Merck and Co Inc · Expires 2007-08-22 · 19y expired

What this patent protects

Hydroxynaphthyridinone carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein L, R<SUP>1a</SUP>, R<SUP>1b</SUP>, R<SUP>1c</SUP>, R<SUP>2a</SUP>, R<SUP>2b</SUP>, R…

USPTO Abstract

Hydroxynaphthyridinone carboxamides of formula: are described as inhibitors of HIV integrase and inhibitors of HIV replication, wherein L, R<SUP>1a</SUP>, R<SUP>1b</SUP>, R<SUP>1c</SUP>, R<SUP>2a</SUP>, R<SUP>2b</SUP>, R<SUP>3</SUP>, R<SUP>4</SUP>, and R<SUP>5 </SUP>are defined herein. These compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

Drugs covered by this patent

Patent Metadata

Patent number
EP1467970B1
Jurisdiction
EP
Classification
Expires
2007-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Merck and Co Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.